Clinical Trials Logo

Peripheral Vascular Diseases clinical trials

View clinical trials related to Peripheral Vascular Diseases.

Filter by:

NCT ID: NCT02869087 Completed - Clinical trials for Peripheral Vascular Disease

The DESappear Study: Drug Eluting Scaffold

DESappear
Start date: October 10, 2016
Phase: N/A
Study type: Interventional

The aim of this study is to prospectively collect information to evaluate the safety and performance of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral scaffold system for the treatment of symptomatic primary atherosclerotic stenoses and occlusions of the superficial femoral artery (SFA).

NCT ID: NCT02864654 Enrolling by invitation - Clinical trials for Peripheral Arterial Disease

Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia

Start date: July 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Adipose-derived regenerative cells (ADRC) will be extracted from lipoaspirate by enzymatic digestion. 10 mL of autologous ADRC suspension injected intramuscularly, close to the site of muscle injury. All patients will receive cell therapy. This is a single arm study with no control.

NCT ID: NCT02856230 Active, not recruiting - Clinical trials for Peripheral Vascular Diseases

An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK)

RANGER-BTK
Start date: November 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Endovascular treatment of below the knee disease is a well-established therapy to improve outcomes in patients with critical limb ischemia. Several large cohort studies demonstrated the safety and the efficacy of percutaneous recanalization and angioplasty for distal vessel disease. A successful recanalization of foot artery was related to a higher ulcer healing and a reduction of major amputation. Moreover absence of revascularization in a patient with critical limb ischemia is an independent risk factor for mortality. Despite the introduction of new devices dedicated to below the knee vessel disease treatment, with the development of guides and conical balloons, long term patency outcomes are still poor. Restenosis was observed in more than two thirds of patients within 3 months after angioplasty of tibial arteries with a high target lesions revascularization. These re-interventions are characterized by a higher morbidity and mortality due to several comorbidities associated to these patients. These data confirm the need to obtain more lasting results in order to improve long-term outcomes of these patients. Recently, the use of drug-eluting balloons (DEB) has revealed an increase in patency after angioplasty of the femoral artery. On the contrary, results for BTK arteries angioplasty have shown controversial results. The purpose of this study is to evaluate the safety and the efficacy of the Ranger™ SL paclitaxel coated balloon a model of drug eluting balloon in patients with critical limb ischemia.

NCT ID: NCT02850432 Recruiting - Clinical trials for Peripheral Arterial Disease

Clinical and MRI Cardiac Biomarkers on Peripheral Arterial Disease in Patients With Long Term DM

CMRPADDM
Start date: May 1, 2016
Phase: N/A
Study type: Interventional

The aim of this study is to establish a clinically feasible simultaneous evaluation of heart and lower limb using MRI and to assess the combined benefit of clinical and cardiac MRI imaging markers in the evaluation of PAD and prediction of treatment outcome.

NCT ID: NCT02850107 Completed - Clinical trials for Peripheral Vascular Disease

DiRectional AthErectomy + Drug CoAted BaLloon to Treat Long, CalcifIed FemoropopliTeal ArterY Lesions

REALITY
Start date: June 1, 2016
Phase: N/A
Study type: Interventional

This study is designed to collect information during a procedure that is routine care for treating a blockage in a blood vessel in the upper part of the participant's leg. This study is for data collection reasons to help doctors gain better understanding of the treatment of disease in the blood vessels of the legs. You will be treated with two devices that are routine, or standard of care, for your doctor to treat blockages in the blood vessel of the leg. The treatment is for a blockage or narrowing caused by plaque build-up in the blood vessel. Data will be collected to assess what length of time the blood vessel will be prevented from re-narrowing through twenty-four (24) months after the procedure.

NCT ID: NCT02842424 Recruiting - Clinical trials for Peripheral Arterial Disease

Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis

Start date: February 25, 2016
Phase: Phase 4
Study type: Interventional

Peripheral artery disease (PAD) is a manifestation of atherosclerosis that produces progressive narrowing and occlusion of the arteries supplying the lower extremities. The most common clinical manifestation of PAD is claudication, i.e., a severe functional limitation identified as gait dysfunction and walking-induced leg muscle pain relieved by rest. The standard therapies for claudication include the medications cilostazol and pentoxifylline, supervised exercise therapy and operative revascularization. Recent data demonstrated that 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor Ramipril produces improvements in the walking performance of patients with claudication that are higher than those of cilostazol and pentoxifylline and similar to those produced by supervised exercise therapy and operative revascularization. The mechanisms by which Ramipril therapy produces this impressive improvement in the functional capacity of claudicating patients remain unknown. The Investigators hypothesize that treatment of claudicating PAD patients with Ramipril will improve walking performance and quality of life by improving the myopathy of the gastrocnemius. Improved myopathy is a consequence of reduced oxidative damage, reduced TGF-β1 production by vascular smooth muscle cells and reduced collagen deposition in the affected gastrocnemius.

NCT ID: NCT02834858 Recruiting - Diabetic Foot Clinical Trials

Umbilical Cord Mesenchymal Stem Cells Infusion for Diabetes Related Vascular Complications

Start date: January 2016
Phase: Phase 1
Study type: Interventional

Stem cell therapy has been a new and effective therapy in recent years for diabetic foot.This study intends to establish an optimal clinical research program, and attempts to break the technical bottleneck in the stem cell therapy for treating diabetes related vascular complications.

NCT ID: NCT02834221 Completed - Atrial Fibrillation Clinical Trials

Ultrasound-guided Femoral Vein Accessibility, Safety and Time for Atrial Fibrillation Treatment

ULTRA-FAST
Start date: June 2016
Phase: N/A
Study type: Interventional

This study is designed to evaluate the use of real-time ultrasound-guided femoral venipuncture during pulmonary vein isolation for treating atrial fibrillation .

NCT ID: NCT02832115 Completed - Clinical trials for Coronary Artery Disease

Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention

TNT-RASP
Start date: September 2016
Phase: Phase 4
Study type: Interventional

The primary objective of the study is to determine the role of transdermal vasodilators as an adjunct to parenteral vasodilators in reducing radial artery spasm, improving patient comfort, and post procedure radial artery patency during transradial coronary angiograms and interventions. The study hypothesis is that transdermal vasodilators will increase radial artery size and reduce radial artery spasm as well as improve patient comfort and post procedure radial artery patency. This is a single-center, double-blind, randomized, placebo-controlled study comparing the effect of transdermal preparations of lidocaine + nitroglycerine and lidocaine + placebo on radial artery spasm in patients undergoing transdermal coronary angiograms. Prior to the procedure, each patient will be randomized into either the control arm, lidocaine + placebo, or study arm, lidocaine + nitroglycerine.

NCT ID: NCT02831075 Recruiting - Diabetic Foot Clinical Trials

A Clinical Study Using Adipose-derived Stem Cells for Diabetic Foot

Start date: January 2015
Phase: Phase 1
Study type: Interventional

Stem cell therapy has been a new and effective therapy in recent years for diabetic foot.This study intends to establish an optimal clinical research program, and attempts to break the technical bottleneck in the stem cell therapy for treating diabetes related vascular complications.